Brain Malignancy Steering Committee clinical trials planning workshop: Report from the Targeted Therapies Working Group Journal Article
| Authors: | Alexander, B. M.; Galanis, E.; Yung, W. K. A.; Ballman, K. V.; Boyett, J. M.; Cloughesy, T. F.; DeGroot, J. F.; Huse, J. T.; Mann, B.; Mason, W.; Mellinghoff, I. K.; Mikkelsen, T.; Mischel, P. S.; O'Neill, B. P.; Prados, M. D.; Sarkaria, J. N.; Tawab-Amiri, A.; Trippa, L.; Ye, X.; Ligon, K. L.; Berry, D. A.; Wen, P. Y. |
| Article Title: | Brain Malignancy Steering Committee clinical trials planning workshop: Report from the Targeted Therapies Working Group |
| Abstract: | Glioblastoma is the most common primary brain malignancy and is associated with poor prognosis despite aggressive local and systemic therapy, which is related to a paucity of viable treatment options in both the newly diagnosed and recurrent settings. Even so, the rapidly increasing number of targeted therapies being evaluated in oncology clinical trials offers hope for the future. Given the broad range of possibilities for future trials, the Brain Malignancy Steering Committee convened a clinical trials planning meeting that was held at the Udvar-Hazy Center in Chantilly, Virginia, on September 19 and 20, 2013. This manuscript reports the deliberations leading up to the event from the Targeted Therapies Working Group and the results of the meeting. © 2014 The Author(s). |
| Keywords: | biomarkers; glioblastoma; clinical trials; adaptive randomization |
| Journal Title: | Neuro-Oncology |
| Volume: | 17 |
| Issue: | 2 |
| ISSN: | 1522-8517 |
| Publisher: | Oxford University Press |
| Date Published: | 2015-02-01 |
| Start Page: | 180 |
| End Page: | 188 |
| Language: | English |
| DOI: | 10.1093/neuonc/nou154 |
| PROVIDER: | scopus |
| PMCID: | PMC4288520 |
| PUBMED: | 25165194 |
| DOI/URL: | |
| Notes: | Export Date: 2 April 2015 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
-
269Mellinghoff -
143Huse
Related MSK Work